Relationship between cell-associated matrix metalloproteinase 9 and psoriatic keratinocyte growth.
Primary cultures of psoriatic keratinocytes proliferated at a higher rate and produced lower amounts of matrix metalloproteinase 9 than normal keratinocytes cultured under similar conditions. Sup- plementation of psoriatic keratinocyte cell culture medium with batimastat or the use of a matrix metalloproteinase 9 blocking antibody further stimulated psoriatic keratinocyte growth. An increase in intracellular ceramide level enhanced matrix metalloproteinase 9 production and inhibited cell proliferation in parallel. Whether cells were treated with sphingomyelinase or not, however, conditioned media from psoriatic keratinocytes contained higher levels of tissue inhibitor of metalloproteinase-1 compared with matrix metalloproteinase 9 and secreted only the proenzyme form. Pro-matrix metalloproteinase 9, as well as active matrix metalloproteinase 9, was identified in membrane preparations of psoriatic keratinocytes, and enzyme amounts were greatly elevated following sphingomyelinase action. As (i) tissue inhibitor of metalloproteinase-1 antibody nearly totally abrogated keratinocyte growth and (ii) complexes of tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase 9 were recovered in membrane extracts of sphingomyelinase-treated psoriatic keratinocytes, we postulate that an increased level of cell-associated matrix metalloproteinase 9 might compete for tissue inhibitor of metalloproteinase-1 binding to its receptor. As a consequence, the increased levels of matrix metalloproteinase 9 will decrease keratinocyte growth.
Buisson-Legendre
N
N
CNRS, UPRESA 6021, IFR53 Biomolecules, Faculté de Médecine, Reims, France.
Emonard
H
H
Bernard
P
P
Hornebeck
W
W
D000328:Adult; D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D006801:Humans; D015603:Keratinocytes / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D020780:Matrix Metalloproteinase 9 / Q000378:metabolism*; D008875:Middle Aged; D011480:Protease Inhibitors / Q000378:metabolism; D011565:Psoriasis / Q000201:enzymology* / Q000473:pathology*; D012016:Reference Values; D013108:Sphingomyelin Phosphodiesterase / Q000494:pharmacology; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000378:metabolism
D011480:Protease Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D013108:Sphingomyelin Phosphodiesterase; D020780:Matrix Metalloproteinase 9